The rheolytic thrombectomy AngioJet™ is a safe and technically feasible method for treating acute and sub-acute occluding lesions in the visceral arteries.

BACKGROUND

The aim of this study is to evaluate the safety and feasibility of the AngioJet™ device in the endovascular treatment of visceral ischemia with stenotic or occlusive lesions.

METHODS

Retrospective analysis of patients treated for visceral artery occlusion with thrombectomy using the AngioJet™ (Boston Scientific, MA, USA). Inclusion criteria: patients with stenotic or occluding lesion in visceral arteries including renal and mesenteric arteries, who received endovascular treatment with AngioJet™.

RESULTS

Eighteen patients with acute and sub-acute visceral arteries occlusions underwent endovascular thrombectomy. In twelve cases the procedure was successful, and the patients were discharged with patent target arteries. Four cases required re-intervention and two cases ended with a fatal complication. The technical and clinical success rate in our study was 88,9% (sixteen out of eighteen), these patients were discharged from hospital with patent target arteries.

CONCLUSIONS

The thrombectomy using the AngioJet™ device is an effective and feasible method for the treatment of stenotic or occluding lesions of the visceral arteries with rapid post-interventional clinical improvement and minimal adverse events.